Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes: A post-hoc analysis of a randomized clinical trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes : A post-hoc analysis of a randomized clinical trial. / Larsen, Emil List; Kjær, Laura K.; Lundby-Christensen, Louise; Boesgaard, Trine W.; Breum, Leif; Gluud, Christian; Hedetoft, Christoffer; Krarup, Thure; Lund, Søren S.; Mathiesen, Elisabeth R.; Perrild, Hans; Sneppen, Simone B.; Tarnow, Lise; Thorsteinsson, Birger; Vestergaard, Henrik; Poulsen, Henrik E.; Madsbad, Sten; Almdal, Thomas P.

I: Free Radical Biology and Medicine, Bind 178, 2022, s. 18-25.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Larsen, EL, Kjær, LK, Lundby-Christensen, L, Boesgaard, TW, Breum, L, Gluud, C, Hedetoft, C, Krarup, T, Lund, SS, Mathiesen, ER, Perrild, H, Sneppen, SB, Tarnow, L, Thorsteinsson, B, Vestergaard, H, Poulsen, HE, Madsbad, S & Almdal, TP 2022, 'Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes: A post-hoc analysis of a randomized clinical trial', Free Radical Biology and Medicine, bind 178, s. 18-25. https://doi.org/10.1016/j.freeradbiomed.2021.11.028

APA

Larsen, E. L., Kjær, L. K., Lundby-Christensen, L., Boesgaard, T. W., Breum, L., Gluud, C., Hedetoft, C., Krarup, T., Lund, S. S., Mathiesen, E. R., Perrild, H., Sneppen, S. B., Tarnow, L., Thorsteinsson, B., Vestergaard, H., Poulsen, H. E., Madsbad, S., & Almdal, T. P. (2022). Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes: A post-hoc analysis of a randomized clinical trial. Free Radical Biology and Medicine, 178, 18-25. https://doi.org/10.1016/j.freeradbiomed.2021.11.028

Vancouver

Larsen EL, Kjær LK, Lundby-Christensen L, Boesgaard TW, Breum L, Gluud C o.a. Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes: A post-hoc analysis of a randomized clinical trial. Free Radical Biology and Medicine. 2022;178:18-25. https://doi.org/10.1016/j.freeradbiomed.2021.11.028

Author

Larsen, Emil List ; Kjær, Laura K. ; Lundby-Christensen, Louise ; Boesgaard, Trine W. ; Breum, Leif ; Gluud, Christian ; Hedetoft, Christoffer ; Krarup, Thure ; Lund, Søren S. ; Mathiesen, Elisabeth R. ; Perrild, Hans ; Sneppen, Simone B. ; Tarnow, Lise ; Thorsteinsson, Birger ; Vestergaard, Henrik ; Poulsen, Henrik E. ; Madsbad, Sten ; Almdal, Thomas P. / Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes : A post-hoc analysis of a randomized clinical trial. I: Free Radical Biology and Medicine. 2022 ; Bind 178. s. 18-25.

Bibtex

@article{413aec3eab45456ba0a5b496ea7d622e,
title = "Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes: A post-hoc analysis of a randomized clinical trial",
abstract = "Formation of reactive oxygen species has been linked to the development of diabetes complications. Treatment with metformin has been associated with a lower risk of developing diabetes complications, including when used in combination with insulin. Metformin inhibits Complex 1 in isolated mitochondria and thereby decreases the formation of reactive oxygen species. Thus, we post-hoc investigated the effect of metformin in combination with different insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes. Four hundred and fifteen individuals with type 2 diabetes were randomized (1:1) to blinded treatment with metformin (1,000 mg twice daily) versus placebo and to (1:1:1) open-label biphasic insulin, basal-bolus insulin, or basal insulin therapy in a 2 × 3 factorial design. RNA and DNA oxidation were determined at baseline and after 18 months measured as urinary excretions of 8-oxo-7,8-dihydroguanosine (8-oxoGuo) and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG), respectively. Urinary excretion of 8-oxoGuo changed by +7.1% (95% CI: 0.5% to 14.0%, P = 0.03) following metformin versus placebo, whereas changes in 8-oxodG were comparable between intervention groups. Biphasic insulin decreased urinary excretion of 8-oxoGuo (within-group: −9.6% (95% CI: −14.4% to −4.4%)) more than basal-bolus insulin (within-group: 5.2% (95% CI: −0.5% to 11.2%)), P = 0.0002 between groups, and basal insulin (within-group: 3.7% (95% CI: −2.0% to 9.7%)), P = 0.0007 between groups. Urinary excretion of 8-oxodG decreased more in the biphasic insulin group (within-group: −9.9% (95% CI: −14.4% to −5.2%)) than basal-bolus insulin (within group effect: −1.2% (95% CI: −6.1% to 3.9%)), P = 0.01 between groups, whereas no difference was observed compared with basal insulin. In conclusion, eighteen months of metformin treatment in addition to different insulin regimens increased RNA oxidation, but not DNA oxidation. Biphasic insulin decreased both RNA and DNA oxidation compared with other insulin regimens.",
keywords = "8-oxodG, 8-oxoGuo, Insulin, Metformin, Oxidative stress, Type 2 diabetes",
author = "Larsen, {Emil List} and Kj{\ae}r, {Laura K.} and Louise Lundby-Christensen and Boesgaard, {Trine W.} and Leif Breum and Christian Gluud and Christoffer Hedetoft and Thure Krarup and Lund, {S{\o}ren S.} and Mathiesen, {Elisabeth R.} and Hans Perrild and Sneppen, {Simone B.} and Lise Tarnow and Birger Thorsteinsson and Henrik Vestergaard and Poulsen, {Henrik E.} and Sten Madsbad and Almdal, {Thomas P.}",
note = "Publisher Copyright: {\textcopyright} 2021",
year = "2022",
doi = "10.1016/j.freeradbiomed.2021.11.028",
language = "English",
volume = "178",
pages = "18--25",
journal = "Free Radical Biology & Medicine",
issn = "0891-5849",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes

T2 - A post-hoc analysis of a randomized clinical trial

AU - Larsen, Emil List

AU - Kjær, Laura K.

AU - Lundby-Christensen, Louise

AU - Boesgaard, Trine W.

AU - Breum, Leif

AU - Gluud, Christian

AU - Hedetoft, Christoffer

AU - Krarup, Thure

AU - Lund, Søren S.

AU - Mathiesen, Elisabeth R.

AU - Perrild, Hans

AU - Sneppen, Simone B.

AU - Tarnow, Lise

AU - Thorsteinsson, Birger

AU - Vestergaard, Henrik

AU - Poulsen, Henrik E.

AU - Madsbad, Sten

AU - Almdal, Thomas P.

N1 - Publisher Copyright: © 2021

PY - 2022

Y1 - 2022

N2 - Formation of reactive oxygen species has been linked to the development of diabetes complications. Treatment with metformin has been associated with a lower risk of developing diabetes complications, including when used in combination with insulin. Metformin inhibits Complex 1 in isolated mitochondria and thereby decreases the formation of reactive oxygen species. Thus, we post-hoc investigated the effect of metformin in combination with different insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes. Four hundred and fifteen individuals with type 2 diabetes were randomized (1:1) to blinded treatment with metformin (1,000 mg twice daily) versus placebo and to (1:1:1) open-label biphasic insulin, basal-bolus insulin, or basal insulin therapy in a 2 × 3 factorial design. RNA and DNA oxidation were determined at baseline and after 18 months measured as urinary excretions of 8-oxo-7,8-dihydroguanosine (8-oxoGuo) and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG), respectively. Urinary excretion of 8-oxoGuo changed by +7.1% (95% CI: 0.5% to 14.0%, P = 0.03) following metformin versus placebo, whereas changes in 8-oxodG were comparable between intervention groups. Biphasic insulin decreased urinary excretion of 8-oxoGuo (within-group: −9.6% (95% CI: −14.4% to −4.4%)) more than basal-bolus insulin (within-group: 5.2% (95% CI: −0.5% to 11.2%)), P = 0.0002 between groups, and basal insulin (within-group: 3.7% (95% CI: −2.0% to 9.7%)), P = 0.0007 between groups. Urinary excretion of 8-oxodG decreased more in the biphasic insulin group (within-group: −9.9% (95% CI: −14.4% to −5.2%)) than basal-bolus insulin (within group effect: −1.2% (95% CI: −6.1% to 3.9%)), P = 0.01 between groups, whereas no difference was observed compared with basal insulin. In conclusion, eighteen months of metformin treatment in addition to different insulin regimens increased RNA oxidation, but not DNA oxidation. Biphasic insulin decreased both RNA and DNA oxidation compared with other insulin regimens.

AB - Formation of reactive oxygen species has been linked to the development of diabetes complications. Treatment with metformin has been associated with a lower risk of developing diabetes complications, including when used in combination with insulin. Metformin inhibits Complex 1 in isolated mitochondria and thereby decreases the formation of reactive oxygen species. Thus, we post-hoc investigated the effect of metformin in combination with different insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes. Four hundred and fifteen individuals with type 2 diabetes were randomized (1:1) to blinded treatment with metformin (1,000 mg twice daily) versus placebo and to (1:1:1) open-label biphasic insulin, basal-bolus insulin, or basal insulin therapy in a 2 × 3 factorial design. RNA and DNA oxidation were determined at baseline and after 18 months measured as urinary excretions of 8-oxo-7,8-dihydroguanosine (8-oxoGuo) and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG), respectively. Urinary excretion of 8-oxoGuo changed by +7.1% (95% CI: 0.5% to 14.0%, P = 0.03) following metformin versus placebo, whereas changes in 8-oxodG were comparable between intervention groups. Biphasic insulin decreased urinary excretion of 8-oxoGuo (within-group: −9.6% (95% CI: −14.4% to −4.4%)) more than basal-bolus insulin (within-group: 5.2% (95% CI: −0.5% to 11.2%)), P = 0.0002 between groups, and basal insulin (within-group: 3.7% (95% CI: −2.0% to 9.7%)), P = 0.0007 between groups. Urinary excretion of 8-oxodG decreased more in the biphasic insulin group (within-group: −9.9% (95% CI: −14.4% to −5.2%)) than basal-bolus insulin (within group effect: −1.2% (95% CI: −6.1% to 3.9%)), P = 0.01 between groups, whereas no difference was observed compared with basal insulin. In conclusion, eighteen months of metformin treatment in addition to different insulin regimens increased RNA oxidation, but not DNA oxidation. Biphasic insulin decreased both RNA and DNA oxidation compared with other insulin regimens.

KW - 8-oxodG

KW - 8-oxoGuo

KW - Insulin

KW - Metformin

KW - Oxidative stress

KW - Type 2 diabetes

U2 - 10.1016/j.freeradbiomed.2021.11.028

DO - 10.1016/j.freeradbiomed.2021.11.028

M3 - Journal article

C2 - 34823018

AN - SCOPUS:85119964495

VL - 178

SP - 18

EP - 25

JO - Free Radical Biology & Medicine

JF - Free Radical Biology & Medicine

SN - 0891-5849

ER -

ID: 288925191